Deserpidine
Enduronyl, Harmonyl, Oreticyl (deserpidine) is a small molecule pharmaceutical. Deserpidine was first approved as Harmonyl on 1982-01-01. It is used to treat dyskinesias, hypertension, and schizophrenia in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deserpidine
Deserpidine
+
Hydrochlorothiazide
Deserpidine
+
Methyclothiazide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ENDURONYL | Abbott Biotherapeutics | N-012775 DISCN | 1982-01-01 | 1 products |
| ENDURONYL FORTE | Abbott Biotherapeutics | N-012775 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02A: Antiadrenergic agents, centrally acting
— C02AA: Rauwolfia alkaloids, centrally acting antiadrenergic
— C02AA05: Deserpidine
— C02L: Antihypertensives and diuretics in combination
— C02LA: Rauwolfia alkaloids and diuretics in combination
— C02LA03: Deserpidine and diuretics
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Deserpidine |
| INN | deserpidine |
| Description | Deserpidine is an alkaloid ester, a methyl ester, a benzoate ester, an organic heteropentacyclic compound and a yohimban alkaloid. It derives from a hydride of a yohimban. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5ccccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC |
Identifiers
| PDB | — |
| CAS-ID | 131-01-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200515 |
| ChEBI ID | 27478 |
| PubChem CID | 8550 |
| DrugBank | DB01089 |
| UNII ID | 9016E3VB47 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Deserpidine
+
Methyclothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 140 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use